AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth CareGeographicals
BenzamidesPiperazinesPyrimidinesSafetyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveGastrointestinal Stromal TumorsSafety ManagementPregnatrienesFusion Proteins, bcr-ablPatient SafetyAntineoplastic AgentsProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaKetonesFuransProtein Kinase InhibitorsLeukemia, Myeloid, Chronic-PhaseReceptor, Platelet-Derived Growth Factor betaTreatment OutcomeFood SafetyHypopigmentationHypereosinophilic SyndromeEquipment SafetyBlast CrisisDrug Resistance, NeoplasmCytogenetic AnalysisGenes, ablErgoloid MesylatesProtein-Tyrosine KinasesGastrointestinal NeoplasmsDeferoxamineProto-Oncogene Proteins c-ablDose-Response Relationship, DrugK562 CellsConsumer Product SafetyAdministration, OralDrug ApprovalMesylatesLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativePergolidePhiladelphia ChromosomeDrug Administration ScheduleDouble-Blind MethodMedical ErrorsRemission InductionFenoldopamEnzyme InhibitorsTime FactorsBenzoxazinesPefloxacinUnited States Food and Drug AdministrationDelavirdineTubulin ModulatorsMastocytosis, SystemicReceptors, Platelet-Derived Growth FactorDermatofibrosarcomaDisease-Free SurvivalNaphthalenesPralidoxime CompoundsNelfinavirQuinolizinesDrug-Related Side Effects and Adverse ReactionsNauseaCell Line, TumorPyrrolesGabexateFibromatosis, AggressiveFollow-Up StudiesProto-Oncogene Proteins c-sisMorpholinesOrganizational CultureAntineoplastic Combined Chemotherapy ProtocolsNational Institute for Occupational Safety and Health (U.S.)Antimitotic AgentsRecurrenceDrug Therapy, CombinationCannabinoid Receptor AgonistsProduct Surveillance, PostmarketingErgolinesSurvival AnalysisApoptosisInfusions, IntravenousProspective StudiesDihydroergotoxineMaximum Tolerated DoseIndolesVomitingCannabinoidsLichenoid EruptionsTreatment FailureBromocriptineNeutropeniaOccupational HealthHarringtoninesInterferon-alphaArea Under CurveCell ProliferationDrug SynergismmRNA Cleavage and Polyadenylation FactorsDisease Progression
KinaseQualityImatinibAdjuvantEfficacyTreatment
Kinase2
  • Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor ( EGFR ) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. (rxlist.com)
  • Osimertinib is a kinase inhibitor for oral use. (rxlist.com)
Quality2
  • We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. (drreddys.com)
  • It is the responsibility of the company making the DS to assure the safety and quality of their products. (oncolink.org)
Imatinib2
  • Imatinib mesylate is one example of a therapy that targets the BCR-ABL1 fusion protein responsible for the growth of some leukemic cells. (basicmedicalkey.com)
  • Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu. (trialstracker.net)
Adjuvant1
  • Any adjuvant or neoadjuvant treatment, whether with osimertinib or platinum-based chemotherapy, would count towards the prior treatment requirement if the participant experienced disease progression within 6 months of the last dose. (who.int)
Efficacy2
  • Its physicochemical properties, mechanism of action and clinical efficacy in the treatment of NSCLC are comparable with similar foreign drugs Gefitinib and Erlotinib, and its safety is even superior to the above two drugs. (sandoopharm.com)
  • The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. (vicc.org)
Treatment2
  • Osimertinib must have been administered as the first EGFR TKI for metastatic disease or as the second TKI after prior treatment with first- or second-generation EGFR TKI in participants with metastatic EGFR T790M mutation positive NSCLC. (who.int)
  • A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin CASP in the Firstline Treatment of probable and proven Invasive Aspergillosis IA in Patients with Hematolo. (trialstracker.net)